1
|
Shai S, Patolsky F, Drori H, Scheinman EJ, Davidovits E, Davidovits G, Tirman S, Arber N, Katz A, Adir Y. A novel, accurate, and non-invasive liquid biopsy test to measure cellular immune responses as a tool to diagnose early-stage lung cancer: a clinical trials study. Respir Res 2023; 24:52. [PMID: 36788537 PMCID: PMC9927051 DOI: 10.1186/s12931-023-02358-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 02/05/2023] [Indexed: 02/16/2023] Open
Abstract
INTRODUCTION Lung cancer remains the leading cause of death from cancer, worldwide. Developing early detection diagnostic methods, especially non-invasive methods, is a critical component to raising the overall survival rate and prognosis for lung cancer. The purpose of this study is to evaluate two protocols of a novel in vitro cellular immune response test to detect lung cancer. The test specifically quantifies the glycolysis metabolism pathway, which is a biomarker for the activation level of immune cells. It summarizes the results of two clinical trials, where each deploys a different protocol's version of this test for the detection of lung cancer. In the later clinical trial, an improved test protocol is applied. METHOD The test platform is based on changes in the metabolic pathways of the immune cells following their activation by antigenic stimuli associated with Lung cancer. Peripheral Blood Mononuclear Cells are loaded on a multiwell plate together with various lung tumor associated antigens and a fluorescent probe that exhibits a pH-dependent absorption shift. The acidification process in the extracellular fluid is monitored by a commercial fluorescence plate reader device in continuous reading for 3 h at 37 °C to document the fluorescent signal received from each well. RESULTS In the later clinical trial, an improved test protocol was applied and resulted in increased test accuracy. Specificity of the test increased to 94.0% and test sensitivity increased to 97.3% in lung cancer stage I, by using the improved protocol. CONCLUSION The improved protocol of the novel cellular immune metabolic response based test detects stage I and stage II of lung cancer with high specificity and sensitivity, with low material costs and fast results.
Collapse
Affiliation(s)
- Shafrira Shai
- Savicell Diagnostics Ltd., Matam Advanced Technology Park, Building #23, P.O. Box 15050, 3190501, Haifa, Israel.
| | - Fernando Patolsky
- grid.12136.370000 0004 1937 0546School of Chemistry, Faculty of Exact Sciences, Tel Aviv University, 69978 Tel Aviv, Israel
| | - Hagai Drori
- Savicell Diagnostics Ltd., Matam Advanced Technology Park, Building #23, P.O. Box 15050, 3190501 Haifa, Israel
| | - Eyal J. Scheinman
- Savicell Diagnostics Ltd., Matam Advanced Technology Park, Building #23, P.O. Box 15050, 3190501 Haifa, Israel
| | - Eyal Davidovits
- Savicell Diagnostics Ltd., Matam Advanced Technology Park, Building #23, P.O. Box 15050, 3190501 Haifa, Israel
| | - Giora Davidovits
- Savicell Diagnostics Ltd., Matam Advanced Technology Park, Building #23, P.O. Box 15050, 3190501 Haifa, Israel
| | - Shoval Tirman
- Savicell Diagnostics Ltd., Matam Advanced Technology Park, Building #23, P.O. Box 15050, 3190501 Haifa, Israel
| | - Nadir Arber
- grid.413449.f0000 0001 0518 6922Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 6423906 Tel Aviv, Israel
| | - Amit Katz
- grid.413731.30000 0000 9950 8111Department of General Thoracic Surgery, Rambam Health Care Campus, 8 HaAliya HaShniya St., PO Box 9602, 31096 Haifa, Israel
| | - Yochai Adir
- grid.413469.dPulmonary Division, Faculty of Medicine, Lady Davis Carmel Medical Center, Mikhal Street 7, 3436212 Haifa, Israel
| |
Collapse
|